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Interferon-alpha, immune activation and immune
dysfunction in treated HIV infection
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Type I interferons (IFNs) exert anti-viral effects through the induction of numerous IFN-stimulated genes and an
immunomodulatory effect on innate and adaptive immune responses. This is beneficial in controlling virus infections but
prolonged IFN-a activity in persistent virus infections, such as HIV infection, may contribute to immune activation and have a
detrimental effect on the function of monocytes and T and B lymphocytes. Activation of monocytes, associated with increased
IFN-a activity, contributes to atherosclerotic vascular disease, brain disease and other ‘age-related diseases’ in HIV patients
treated with long-term antiretroviral therapy (ART). In HIV patients receiving ART, the anti-viral effects of IFN-a therapy have
the potential to contribute to eradication of HIV infection while IFN-a inhibitor therapy is under investigation for the treatment
of immune activation. The management of HIV patients receiving ART will be improved by understanding more about the
opposing effects of IFN-a on HIV infection and disease and by developing methods to assess IFN-a activity in clinical practice.
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Infection by HIVs and simian immunodeficiency viruses (SIVs)
causes immune dysfunction in hosts that are susceptible to disease.
Depletion of CD4þ T cells is the most important immune defect and
the major contributor to AIDS that these infections cause. Direct
infection and destruction of CD4þ T cells, particularly the central
memory subpopulation, contributes to the depletion of CD4þ
T cells, especially in early HIV infection. However, immune activation
and activation-induced cell death are also major contributors to
this process. Immune activation is also associated with chronic
inflammation and activation of the coagulation system that increase
the risk of ‘serious non-AIDS events’ such as atherosclerotic vascular
disease, osteoporosis, osteonecrosis and chronic kidney disease.1
Inflammation also affects lymphoid tissue where the resultant tissue
fibrosis is a cause of impaired homoeostasis of CD4þ T cells2 and
probably memory B cells.
Suppression of HIV infection by combination antiretroviral therapy
(ART) decreases immune activation and inflammation and increases
CD4þ T-cell numbers in most patients. However, CD4þ T-cell
deficiency persists in up to 40% of patients receiving ART, particularly
those patients who commenced ART with a very low CD4þ T-cell
count,3 and is associated with persistent immune activation and an
increased risk of ‘serious non-AIDS events’. A substantial amount of
evidence implicates increased interferon-alpha (IFN-a) activity as a
cause of immune activation and immune dysfunction in HIV
patients. Persistence of these immune defects in patients receiving
ART might therefore be amenable to therapeutic blockade of IFN-a or
its receptors. However, managing this therapy in clinical practice will
be problematic, because IFN-a also possesses anti-viral effects that
may be beneficial in the control of HIV infection and other virus
infections.
IFN-a IN ANTIVIRAL RESPONSES
IFN-a consists of a family of type I IFNs that are encoded by 13 IFN-a
subtype genes in humans,4 who also possess one IFN-b, IFN-e, IFN-k
and IFN-o gene. Human IFN-a proteins are encoded by intronless
genes clustered on human chromosome 9 and share an a-helical
structure of approximately 80% conserved 166 amino acids. Most
IFN-a subtypes are inducible, acid stable and exhibit antiviral,
antiproliferative and immunomodulatory activities.4,5 Differential
expression profiles of type I IFN subtypes have been found in
rhesus macaques infected with SIV,6 but the effects of different IFN-
a subtypes in the pathogenesis of SIV and HIV disease is unclear.
Despite different biological effects, all type I IFNs share a surface
receptor composed of two IFN-a receptor subunits (IFNAR1 and
IFNAR2), which can be either anchored in the cell membrane or shed
as a truncated soluble form.7
Normal type I IFN signalling pathways begin with ligand binding
through the receptor chains to form a stable ternary complex,
followed by activation of the Janus (Jak) tyrosine kinases (Tyk2 and
Jak1). Subsequent attraction and phosphorylation of signal transducer
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and activator of transcription (STAT) molecules leads to the forma-
tion of heterodimers, which disassociate from the receptors and
translocate to the nucleus to complex with interferon regulatory
factor 9 (IRF9), which in turn forms the transcription factor
interferon-stimulated gene factor 3 (ISGF3) that activates transcrip-
tion of IFN-stimulated genes (ISGs) via recognition of upstream
sequence elements in promoters. Differential biological activities of
IFN subtypes may be explained in part by signalling differences in
STAT and mitogen-activated protein kinase activation, with various
tyrosine phosphorylation events found among the IFN subtypes and/
or an association of different binding affinities of subtypes to their
receptor.8
The overall antiviral activities of type I IFNs are complex with
individual human IFN-a subtypes having been found to differ in their
antiviral potency associated with virus-specific expression levels of
ISG subsets, and some ISGs being antiviral while others actually
enhance virus replication in vitro.9 In our studies of retroviruses in
mice, the antiviral activities of subtypes in vitro did not always
correlate with in vivo activities during acute Friend virus infection,
with IFN-a5 and IFN-a6 incapable of reducing viral loads. Indeed,
the antiviral capacity of IFN subtypes IFN-a1, IFN-a4, IFN-a9 and
IFN-a11 were shown to depend on ISG expression as well as
enhancement of natural killer (NK) cell and virus-specific CD8þ
T-cell responses.5 It is noteworthy that most viruses have evolved
strategies to evade type I IFN responses through mechanisms of direct
blockade of induction, inhibition of signalling pathways or prevention
of ISG expression. Perhaps numerous IFN-a subtypes have been
maintained throughout evolutionary history as a survival strategy: an
arsenal of responses against different viruses with specific type I IFN
subtypes capable of inducing subsets of ISGs that are more effective at
inhibiting different viruses.
Although viruses can evade immediate antiviral activities of type I
IFNs, IFN-a has significant therapeutic potential, in combination
with anti-viral drugs, for controlling infections by viruses, including
HIV. However, low levels of virus persistence during chronic viral
infections, especially in immune cells which are not compartmenta-
lized, may influence the immunomodulatory effects of type I IFNs.
During disease progression, modification of type I IFN pathways,
either virus or immune-mediated, results in lower levels of IFNAR
occupancy producing responses that may lead to immunopathology.
BIOLOGICAL PROPERTIES OF IFN-a
Although original interest was in the antiviral properties of type I
IFNs, many ISGs have also been linked to the pathogenesis of
infectious disease, inflammatory disorders, autoimmune diseases
and cancers.10 The regulation and modulation of type I IFN
production is intricate and involves a cascade of sensor molecules,
adaptors, kinases and transcription factors, which drive the acute
innate response and sculpt the adaptive immune response.
Redundancy in type I IFN signalling pathways coupled with their
pleiotropic properties make definitive roles of such molecules elusive
at the single cell level. The avidity of binding, competition for
cytosolic molecules and timing of activation by kinase
phosphorylation all influence production levels of type I IFNs.10
The products of many virus-induced ISGs are antiviral and clearly
established biomarkers found in the blood of patients with productive
virus infections. Other functions of IFN-a include modulation of
both innate and adaptive immune responses, activating monocytes,
antigen-presenting cells, dendritic cells (DCs), macrophages, NK cells,
T cells and B cells, with stimulation of antibody class switching.11
Cross-talk between type I IFNs is associated with an ISG expression
signature dependent on cell types. For example, exposure of
macrophages to continuous low levels of IFN-a leads to enhanced
IFN-g induction of interleukin (IL)-12p70 through favoured
STAT1 homodimer formation, in contrast to exposure to high levels
of type I IFN, which inhibits IFN-g-induced activation of major
histocompatibility complex (MHC) class II expression and dampens
IL-12p70 production.12 Thus, virus infections induce immune
responses by eliciting production of type I IFNs, which in turn
exert effects that include sustained clonal expansion, differentiation
and survival of proliferating cells. However, type I IFNs may also exert
pro-apoptotic and anti-proliferative effects and sustained production
may adversely affect cell viability and functions such as autophagy, cell
migration and vasculogenesis. Thus, type I IFN has a critical role in
survival from an acute virulent virus infection, but in persistent viral
infections, chronic exposure to type I IFN activity may impair
‘protective’ immune responses against the virus13 and result in host
susceptibility to collateral damage.
CONTROL OF HIV INFECTION BY IFN-STIMULATED GENES
Numerous intracellular anti-viral restriction factors contribute
to the control of HIV infection, including several that are ISGs.
These include apolipoprotein B mRNA-editing, enzyme-catalytic,
polypeptide-like 3 family proteins, which restrict HIV replication in
DCs,14 MX2, which exerts post-entry inhibition of HIV infection,15,16
and bone marrow stromal cell antigen 2 (also known as tetherin),
which restricts release of HIV-1 from infected cells.17
IFN-a AND IMMUNE DYSFUNCTION IN HIV AND SIV
INFECTION
Immune activation is a characteristic of HIV disease and has been
most clearly demonstrated by the altered expression of ‘activation
markers’, such as CD38 and HLA-DR, on the surface of T cells.
However, the underlying causative mechanisms remain unclear. There
is strong evidence that microbial translocation from the gut, co-
infections (for example, cytomegalovirus, hepatitis C virus and
hepatitis B virus) and persistent low-level HIV replication contribute
to residual immune activation to one degree or another in treated
HIV patients.1 All can induce IFN-a activity and ISG expression,
which may elevate other markers of immune activation and promote
disease progression.
Many different cells produce IFN-a but plasmacytoid DCs (pDC)
produce up to 1000-fold more than other cell types. As pDC express
the CD4 receptor, they are susceptible to infection by HIV via binding
of the gp120 envelope protein of the HIV virion to CD4. Conse-
quently, frequencies of peripheral pDC decline as HIV infection
progresses,18–20 and this loss may not be reversed with the
administration of ART.21,22 Loss of pDC is thought to be a result of
both the apoptosis of pDC following their direct infection by HIV23
and the redistribution of pDC from the peripheral circulation to
secondary lymphoid organs in response to HIV-induced upregulation
of the migration marker CCR7.24,25
Despite the reduction in circulating pDC frequencies, IFN-a
production is markedly increased in acute and chronically infected
HIV-positive individuals as a result of HIV-induced pDC hyperacti-
vation. Several studies have documented an increase in IFN-a mRNA
from peripheral pDCs in HIV infection, complemented by markedly
higher IFN-a levels in serum from untreated acutely and chronically
infected patients.20,26,27 HIV infection may even induce a distinct
signature of IFN-a activity, with evidence suggesting that specific
upregulation of the IFN-a subtypes, IFN-a2 and IFN-a6, is observed
in both the acute and chronic phases of untreated disease.28
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Correspondingly, ISGs are upregulated in CD4þ and CD8þ T-cell
subpopulations,29–31 monocytes and DCs31,32 in untreated HIV
infection. The amount of ISGs positively correlates with HIV viral
load and inversely correlates with CD4þ T-cell counts.31 Further
evidence of a role for increased IFN-a activity in causing HIV-
induced immune dysfunction has been obtained from animal models;
persistent upregulation of ISGs in CD4þ T cells and elevated levels of
IFN-a are observed in SIV-infected rhesus macaques (which are not
natural hosts and develop AIDS) but not in SIV-infected African
green monkeys (which are natural hosts and do not progress to
AIDS).33
Our own studies have demonstrated that ISG expression is not
normalized by ART, with elevated levels of ISGs (ISG56, IFI16 and
IFI27) observed in CD4þ and CD8þ T cells isolated from HIV
patients on long-term (434 months) ART when compared with age-
matched healthy donors.34 The dynamics of ISG expression within
different cell subsets is also important as ISG transcript expression
was markedly higher in CD4þ T cells isolated from patients with low
recovery of CD4þ T cells. In contrast, ISG transcript expression in
CD8þ T cells was equally elevated in HIV patients with either low or
normal CD4þ T-cell counts on ART.34
Whether this sustained augmentation of IFN-a activity is beneficial
or detrimental to HIV disease progression is a topic of debate and
ongoing research study (Table 1). Upon initial infection, IFN-a
increases MHC class I and II expression on monocytes, stimulates
the development and activation of NK cells and DCs, activates TH1
cells and induces differentiation of B cells to plasma cells. Further-
more, IFN-a induces or enhances the expression of restriction factors,
which inhibit viral integration and release after reproducing in
infected CD4þ T cells (see above).
More recently, the role that IFN-a has in establishing chronic
immune activation and contributing to the progressive depletion of
various lymphocyte populations in the context of HIV disease has
been considered. Links between IFN-a activity and T-cell activation
are evident in a number of studies. For example, in a cohort of
hepatitis C-infected patients treated with pegylated IFN-a over
28 weeks, a progressive upregulation of CD38 expression on CD8þ
T cells was observed.26 Blocking the IFN-a receptors (IFNAR1 and
IFNAR2) prevented induction of the activation markers, CD38 and
CD69, by HIV-exposed CD4þ and CD8þ T cells.35
In addition, the immunomodulatory functions of IFN-a may also
contribute to CD4þ T-cell depletion in chronic HIV infection and
prevent immune reconstitution. Herbeuval et al.36 have proposed that
IFN-a non-specifically induces the expression of TNF-related
apoptosis-inducing ligand (TRAIL) mediated by IFNAR/STAT1 and
STAT3 signalling while, simultaneously, the binding of HIV to the
CD4 receptor upregulates its ligand, death receptor 5 (DR5). The
TRAIL expressed on CD4þ T cells and monocytes bind to DR5 and
induce apoptosis. This concept is not limited to CD4þ T cells as
TRAIL-mediated apoptosis has also been implicated in inhibiting
memory B-cell reconstitution in successfully treated HIV patients.37
In vitro exposure of peripheral blood mononuclear cells to IFN-a also
upregulates the expression of pro-apoptotic molecules Bak and Fas
(CD95) on CD4þ T cells and subsequently promotes Fas-mediated
apoptosis of T cells from HIV patients.38 Bak is upregulated on
CD4þ T cells in chronic HIV infection, and its expression is
associated with CD4þ T-cell loss.38
Furthermore, our own in vitro studies suggest that IFN-a can
enhance activation-induced proliferation (via T-cell-receptor stimula-
tion) but inhibit homoeostatic proliferation (IL-7-induced) of T-cells.
Both of these effects may adversely affect CD4þ T-cell homoeostasis
in HIV patients, promoting the loss of T cells by accelerating cell
turnover and activation-induced cell death, and decreasing the
renewal of T cells by inhibiting the proliferative effects of IL-7.39
MONOCYTE ACTIVATION AND IFN-a IN ATHEROSCLEROTIC
VASCULAR DISEASE AND NEUROLOGICAL DISEASE IN HIV
PATIENTS
Monocytes are innate immune cells of the myeloid lineage that arise
from a precursor stem cell population that also produces macro-
phages and DCs. Within this differentiation pathway, monocytes serve
as a circulating source of professional antigen-presenting cells in
tissues, including tissue-resident macrophages (such as brain micro-
glial cells) and monocyte-derived DCs. One of the defining properties
of monocytes is their ability to respond to infection and inflammation
by crossing epithelial barriers to enter tissue compartments, including
sites of ‘immune privilege’ such as the central nervous system. This is
of relevance in the context of HIV infection, as monocytes may
promote initial transmission through genital tract epithelial barriers
in acute infection,40 and are then thought to have a major role in
seeding HIV infection in the central nervous system during chronic
infection.41
Circulating monocytes are generally short-lived with a half-life of
around 3 days, although their ‘default’ apoptotic programme is
readily overcome by inflammatory signals that can then promote
differentiation into long-lived macrophages and monocyte-derived
DCs, as well as the maturation of longer-lived monocyte popula-
tions.42 Resolution of inflammation generally leads to resumption of
the apoptotic programme in acute infection, although chronic
infection (as in HIV infection) and even chronic non-infectious
inflammation (as in cardiovascular disease) can lead to persistent
skewing of monocyte differentiation from the dominant ‘classical’
monocyte population identified by strong expression of CD14 (a
lipopolysaccharide receptor) towards ‘non-classical’ monocytes that
express CD14 and CD16 (a low-affinity Fc receptor) and are capable
of increased production of TNF-a and IL-1.42 These CD16þ
monocyte subpopulations are most permissive of HIV infection43
and are also capable of transferring infection into the central nervous
system.41 Interestingly, the phenotype of HIV-induced CD16þ
monocytes is also reproduced in acute coronary syndromes,44
Table 1 Interferon-a exerts both beneficial and deleterious effects on HIV infection
Effects of IFN-a associated with control of HIV infection Effects of IFN-a associated with immune activation and dysfunction in HIV infection
Post-entry inhibition of HIV infection by MX2 Increased expression of CD38 on CD8þ T cells
Restriction of HIV replication in dendritic cells by APOBEC3 family proteins TRAIL-induced apoptosis of CD4þ T cells and memory B cells
Restriction of HIV-1 release by BST-2 Increased expression of Bak in T cells leading to Fas-dependant apoptosis
IFN-a-dependant NK cell activation Increased activation-induced, but decreased IL-7-induced, proliferation of T cells
Abbreviations: APOBEC3, apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3; BST-2, bone marrow stromal cell antigen 2; IFN, interferon; IL, interleukin; NK, natural killer;
TRAIL, tumour necrosis factor-related apoptosis-inducing ligand.
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suggesting that chronic HIV infection produces an inflammatory
response that may contribute to a range of prevalent long-term
diseases, including ‘serious non-AIDS events’, where systemic immune
activation is a common factor. Analysis of monocyte gene expression
in individuals with active HIV-1 infection has demonstrated a
dominant IFN-a signature.32
It is notable that several monocyte-derived plasma biomarkers have
potential clinical relevance in HIV management, including soluble (s)
CD14 which is a strong predictor of all-cause mortality in both
HIVþ subjects45 as well as in the general population.46 Importantly,
treatment of HIV infection and attainment of undetectable HIV viral
load levels does not necessarily correct the abnormal plasma sCD14
signal,47 suggesting that there is residual monocyte activation even in
the context of what would be considered ‘successful’ HIV therapy.
Similarly, elevated levels of sCD163 (a monocyte scavenger receptor)
have been linked to risk of cardiovascular disease and arterial
inflammation48 as well as neurocognitive impairment,49 including
patients on effective ART. Analysis of monocyte gene expression
profiles in chronic HIV infection has demonstrated an IFN-a-induced
activation phenotype that correlates with markers of brain neuronal
injury in vivo.50
Effective ART can correct some aspects of the chronic inflamma-
tory response in HIV infection, including restoration of plasma IFN-a
levels to normal26 and reduction in the proportion of CD16-
expressing monocytes.44 Nevertheless, it is clear that sCD14 and
sCD163 levels remain elevated despite HIV treatment and also
maintain their associations with adverse cardiovascular and
neurological outcomes in this context. Data from the Strategies for
Management of Antiretroviral Therapy study demonstrated that
subjects with the highest quartile of sCD14 levels had a sixfold
higher risk of death than did those in the lowest quartile, with
minimal change after adjustment for other inflammatory markers,
CD4þ T-cell count and plasma HIV RNA level.45 One interesting
approach to improving these outcomes has been to consider the
ability of antiretroviral agents to penetrate monocyte/macrophage cell
populations, using a ‘monocyte efficacy score’.51 Preliminary findings
suggest that this approach provides greater predictive value for
cognitive performance during long-term HIV treatment,51 so it is
hoped that future studies can further validate both determinations of
‘monocyte efficacy’ as well as its clinical application.
These data provide a strong argument that innate immune
activation, caused in part by increased IFN-a activity, persists
throughout the course of HIV infection, albeit with some modifica-
tion by ART. This aspect of chronic HIV infection, while undoubtedly
of prognostic importance,45 is currently ‘invisible’ in routine clinical
management but should not remain so. Understanding the critical
(and measurable) components of this response should lead to novel
monitoring and therapeutic strategies that have the potential to shift
the HIV management paradigm, 20 years after the last revolutionary
advance with the introduction of ART.
ENHANCING AND CONTROLLING IFN-a ACTIVITY IN HIV
PATIENTS RECEIVING ART: A TREATMENT CONUNDRUM IN
EVOLUTION
IFN-a exerts anti-viral activities but also contributes to HIV-induced
immune activation. Consequently, both recombinant IFN-a and
IFN-a inhibitors are being assessed as therapy to enhance the
eradication of HIV infection or immune reconstitution in HIV
patients receiving ART.
Administration of pegylated IFN-a-2a therapy for at least 12 weeks,
and up to 24 weeks, in patients with HIV infection controlled by ART
and a CD4þ T-cell count of 4450ml1 resulted in control of HIV
replication after ART was ceased in 9 out of 20 (45%) subjects as well
as decreased HIV-1 integration.52 In another study, HIV-1 DNA levels
in CD4þ T cells declined in 12 patients with HIV/HCV co-infection
after pegylated IFN-a therapy and ribavirin was added to effective
ART.53 Such findings suggest that IFN-a therapy might be used as a
component of eradication therapy in patients who achieve good
recovery of CD4þ T cells on ART, though clinical trials in larger
numbers of patients and for longer periods of time are needed. In
contrast, patients with suboptimal CD4þ T-cell recovery and/or
persistent immune activation may benefit from therapy that inhibits
IFN-a activity.
The rationale for examining IFN-a inhibitors in patients with HIV
infection is strongly supported by the findings of studies conducted in
patients with autoimmune connective tissue diseases. Patients with
systemic lupus erythematosus (SLE), rheumatoid arthritis, dermato-
myositis, polymyositis and systemic sclerosis exhibit evidence of
increased IFN-a activity,54 and there is compelling evidence that
this has a role in the immunopathogenesis of SLE.55 Increased
IFN-a activity also appears to be a cause of atherosclerotic vascular
disease in patients with SLE.56,57 Inhibition of pDC activation and
IFN-a production are dominant effects of the anti-malarial drug
hydroxychloroquine,58 which has been a fundamental component of
therapy for SLE for over 50 years and reduces the risk of
atherosclerotic vascular disease.59 More recently, interest has
focussed on the use of monoclonal antibodies that inhibit the
effects of IFN-a. Sifalimumab and Rontalizumab are humanized
IgG1k monoclonal antibodies that neutralize IFN-a and reduce
expression of ISGs in tissues and/or blood leucocytes when
administered to patients with SLE60–62 or dermatomyositis/
polymyositis.63
In vitro studies have demonstrated that both hydroxychloroquine
and chloroquine decrease HIV-induced activation of pDCs through
inhibition of Toll-like receptor 7 (TLR-7) signalling, which results in
lower expression of the immunosuppressive molecules indoleamine
2,3-dioxygenase and programmed death ligand 1 and reduced IFN-a
production.25,64 Hydroxychloroquine may inhibit TLR signalling by
binding to nucleic acids and masking their TLR-binding region.65
Although inhibition of TLR-7 signalling might have beneficial effects
on immune activation, clinical trials in patients with HIV infection
suggest that it also has adverse effects on immune responses against
viral infections, including HIV infection.
In a nonrandomized clinical trial conducted in 20 HIV patients
with persistent CD4þ T-cell deficiency despite suppressive ART,
administration of hydroxychoroquine was associated with a reduction
in several markers of immune activation without increasing HIV
replication, even though it had no short-term effect on CD4þ T-cell
recovery.66 Chloroquine also decreased T-cell activation and
proliferation in a small randomized controlled trial conducted in 13
HIV patients not receiving ART.67 In contrast, a randomized placebo-
controlled trial of hydroxychloroquine in 83 untreated HIV patients
demonstrated no change in CD8þ and CD4þ T-cell activation and
proliferation, an increase in plasma HIV RNA levels and a decrease in
CD4þ T-cell counts.68 Furthermore, in the latter study, patients
receiving hydroxychloroquine experienced more frequent episodes of
flu-like illness. Similarly, chloroquine therapy in rhesus macaques
with acute SIV infection resulted in a temporary increase in ISGs and
poorer recovery of CD4þ T cells.69 Taken together, the findings of
these studies suggest that inhibition of IFN-a production by
hydroxychloroquine or chloroquine has detrimental effects on the
control of HIV or SIV replication but might suppress immune
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activation associated with increased IFN-a activity in HIV patients
receiving ART that optimally suppresses HIV replication. However, it
should be noted that the anti-inflammatory effects of
hydroxychloroquine or chloroquine have not been directly related
to inhibition of IFN-a. Clinical trials of IFN-a inhibitors, including
monoclonal antibodies to IFN-a, are currently being conducted in, or
are being planned for, patients receiving ART who have optimally
suppressed HIV infection.
CONCLUSIONS
Continuous production of IFN-a is a prominent feature of chronic
HIV infection and, like SLE, may contribute to immune activation
leading to immune dysfunction and premature bone, brain and
atherosclerotic vascular disease. Blocking type I IFN signalling may
reduce both the ISG gene signature and disease manifestations. A
better understanding of the paradoxical roles of type I IFNs, and the
ISGs serving as signposts along the road to disease progression, may
provide a more rational therapeutic approach to targeting residual
immune activation and dysfunction in HIV patients receiving ART.
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